Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels: The prospective pravastatin pooling project

European Heart Journal

Volumn 23, Issue 3, 2002, Pages 207-215

  Simes, J ^a   Furberg, C D ^b   Braunwald, E ^c   Davis, B R ^d   Ford, I ^e   Tonkin, A ^f   Shepherd, J ^e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WAKE FOREST UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

Author keywords

Cholesterol; Clinical trial; Coronary disease; Lipids; Meta analysis; Mortality

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

AGED; CHOLESTEROL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PREVALENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036488096     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2775     Document Type: Article

References (16)

1. Stamler J, Wentworth D, Neaton JD Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
2. Law MR, Wald NJ, Thompson SG By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-72.
3. Peto R, Yusuf S, Collins R Cholesterol lowering trial results in their epidemiological context. Circulation 1985; 72(Suppl III): III-51.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
5. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
6. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
7. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
8. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615-21.
9. The PPP Project Investigators. Design, rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project: a combined analysis of three large-scale randomized trials: Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995; 76: 899-905.
10. Sacks FM, Tonkin AM, Shepherd J et al. The effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-900.
11. Bucher HC, Griffith LE, Guyatt G Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187-95.
12. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-8.
13. Rosenson RS, Tangney CC Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
14. Simes RJ for the PPP and CTT Investigators. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) project and the Cholesterol Treatment Trialists (CTT) Collaboration. Am J Cardiol 1995; 76S: 122C-6C.
15. Pogue J, Yusuf S Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet 1998; 351: 47-52.
16. Caro J, Klittich W, McGuire A et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-82.